Clinical Trial Update: Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating nivolumab plus relatlimab or nivolumab plus ipilimumab in metastatic melanoma stratified by MHC-II expression.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Relatlimab (relatlimab)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Elizabeth Davis | Conditions: Metastatic Melanoma, Advanced Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2021-03-05